Japanese Journal of Ophthalmology最新文献

{"title":"Assessment of retinal, choroidal and peripapillary microvascular changes in patients with chronic myeloid leukemia.","authors":"Meryem Feyza Cicek, Turker Oba, Fatma Feyza Nur Keskin Perk, Mesut Ayer, Feyza Onder","doi":"10.1007/s10384-025-01216-0","DOIUrl":"10.1007/s10384-025-01216-0","url":null,"abstract":"<p><strong>Purpose: </strong>To quantitatively assess the microvascular alterations and structural parameters in the optic disc, retina, and choriocapillaris of chronic myeloid leukemia (CML) patients devoid of leukemic retinopathy, while also examining the correlation between these parameters and serum laboratory results.</p><p><strong>Study design: </strong>Prospective, cross-sectional, observational clinical study METHODS: This study included 30 eyes from 15 patients diagnosed with CML and 30 eyes from age 15- and gender-matched healthy individuals (control group). All participants underwent comprehensive ophthalmologic assessments, including optical coherence tomography angiography (OCTA). Statistical analyses, including Student's t-test and the Mann-Whitney U test, were conducted to compare structural and vascular parameters between CML patients and controls. Spearman's correlation was used to evaluate the relationship between OCTA measurements and serum parameters.</p><p><strong>Results: </strong>The analysis of macular vessel density revealed significant reductions in all assessed parameters in the patient group compared to the control group. These parameters include whole image superficial vessel density (wisVD, p=0.005), parafoveal superficial vessel density (pfsVD, p=0.002), perifoveal superficial vessel density (pefsVD, p=0.007), whole image deep vessel density (widVD, p=0.005), parafoveal deep vessel density (pfdVD, p=0.004), and perifoveal deep vessel density (pefdVD, p=0.005). Higher white blood cell levels were associated with lower optic nerve head whole image VD, wisVD, pfsVD, pefsVD, widVD, and pefdVD. Higher platelet levels were correlated with lower widVD. Additionally, hemoglobin showed a positive correlation with choriocapillaris vessel flow density, while it exhibited a negative correlation with superior and inferior macular ganglion cell complex thickness.</p><p><strong>Conclusion: </strong>Subclinical retinal perfusion loss was observed in CML patients, and this perfusion loss was associated with hematological parameters. The marked reduction in macular perfusion could be valuable for understanding the pathogenesis of the disease and predicting potential retinal complications such as hypoxia and ischemia in more advanced stages. Further studies are needed to investigate the functional and prognostic significance of the changes we observed.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"745-754"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative study of efficacy and safety of pulse versus half-pulse steroid therapy for Vogt-Koyanagi-Harada Disease.","authors":"Kinya Tsubota, Hiroshi Goto, Masaki Asakage, Yuto Kinoshita, Ryota Nonaka, Kei Wakatsuki, Risa Sugawara, Ryosuke Fukai, Yoshihiko Usui","doi":"10.1007/s10384-025-01213-3","DOIUrl":"10.1007/s10384-025-01213-3","url":null,"abstract":"<p><strong>Purpose: </strong>High-dose steroid therapy is commonly used for Vogt-Koyanagi-Harada (VKH) disease in Japan, but the optimal initial dose remains uncertain. This study investigated the efficacy and safety of conventional steroid pulse therapy (pulse group) and half-dose steroid pulse therapy (half-pulse group) for the initial treatment of VKH disease.</p><p><strong>Study design: </strong>This was a single-center, retrospective observational study based on a review of medical records.</p><p><strong>Subjects and methods: </strong>Seventy-two patients with initial-onset VKH disease treated at Tokyo Medical University Hospital were analyzed. The pulse group (44 patients) received 1000 mg/day of intravenous methylprednisolone (MPSL), while the half-pulse group (28 patients) received 500 mg/day of MPSL. In both groups, steroids were tapered according to ocular findings, and the minimum follow-up period was eight months.</p><p><strong>Results: </strong>Recurrence rate during follow-up period (pulse group: 41%, half-pulse group: 34%, p = 0.48), mean number of recurrences (pulse group: 1.9 ± 1.2, half-pulse group: 1.5 ± 0.9, p = 0.42), and type of recurrence (anterior uveitis: pulse group: 11%, half-pulse group: 17%, p = 0.33; posterior inflammation: pulse group: 34%, half-pulse group: 22%, p = 0.14) were not significantly different between the two groups. The proportion of patients requiring cataract surgery during the follow-up period tended to be higher in the pulse group (pulse group: 10%, half-pulse group: 3%, p = 0.12), although not significantly different. The incidence of sunset glow fundus was not significantly different between the two groups (pulse group: 23%, half-pulse group: 10%, p = 0.22).</p><p><strong>Conclusions: </strong>No significant difference in clinical efficacy for VKH disease was observed between conventional steroid pulse therapy and half-pulse therapy, and by reducing the total steroid dose, half-pulse therapy potentially lowers the risk of adverse effects related corticosteroid.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"805-812"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12391172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Descemet membrane endothelial keratoplasty after cataract surgery with presbyopia-correcting intraocular lens for coexisting Fuchs endothelial corneal dystrophy and cataract.","authors":"Hideaki Yokogawa, Takahiko Hayashi, Akira Kobayashi, Natsuko Mori, Kenichiro Yamazaki, Hirohito Ohta, Masato Takeda, Ami Igarashi, Satoru Yamagami","doi":"10.1007/s10384-025-01215-1","DOIUrl":"10.1007/s10384-025-01215-1","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the outcomes of Descemet membrane endothelial keratoplasty (DMEK) staged after implantation of presbyopia-correcting intraocular lenses (IOLs) in patients with coexisting Fuchs endothelial corneal dystrophy (FECD) and cataract.</p><p><strong>Study design: </strong>Retrospective, interventional case series METHODS: We enrolled six eyes of three patients with coexisting FECD and cataract (3 women, age 67.8 ± 6.5 years) treated with presbyopia-correcting IOL implantation, followed by DMEK. The modified Krachmer grade, visual outcomes, and incidence of intra- and postoperative complications were analyzed.</p><p><strong>Results: </strong>Modified Krachmer FECD grades 4, 5, and 6 were observed in one, two, and three eyes, respectively. The mean best-corrected visual acuity (BCVA) was dissatisfactory with the primary presbyopia-correcting IOL (decimal 0.45), it improved significantly (decimal 1.0, P = 0.027) after DMEK and all eyes acquired satisfactory uncorrected distance and near (30 cm) vision (mean, decimal, distance 0.85 and near 0.56). The manifest spherical equivalent after DMEK was within the acceptable range (-0.375 D to 0.0 D). Rebubbling was required in four eyes, but no instances of other postoperative complications or primary graft failure were encountered.</p><p><strong>Conclusion: </strong>DMEK staged after implantation of presbyopia-correcting IOLs is a viable option for patients with coexisting FECD and cataract.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"702-707"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biometric risk factors for myopia onset in emmetropic school-age children.","authors":"Yoshinori Nakai, Osamu Hieda, Yo Nakamura, Mitsuko Nakata, Chie Sotozono, Shigeru Kinoshita","doi":"10.1007/s10384-025-01222-2","DOIUrl":"10.1007/s10384-025-01222-2","url":null,"abstract":"<p><strong>Purpose: </strong>To identify the potential biometric risk factors for the onset of myopia in emmetropic school-age children.</p><p><strong>Study design: </strong>Longitudinal study.</p><p><strong>Methods: </strong>First, we performed a preliminary study in which objective refraction, corneal refractive power, higher-order aberrations (HOAs), and axial length (AL) was measured annually in 98 Grade-3 (age 8) elementary schoolchildren over a 4-year period from 2006 to 2009. We also examined the refractive changes over 3 years, and assessed the correlation between those changes and the baseline data. Based on those findings, we performed the primary study in which objective and subjective refraction, corneal refractive power, HOAs, and AL was measured annually in Grade 1 (age 6) through Grade 8 (age 13) schoolchildren from 2013 to 2022. We investigated the risk factors for AL elongation over 1 year in children with emmetropia at the first year using a multivariable linear mixed model.</p><p><strong>Results: </strong>Findings in the preliminary study revealed that AL in the first year (age 8) had the strongest correlation with myopia progression for 3 years. The risk factors for AL elongation among emmetropia were 1) lower grade, 2) sex (female), 3) myopic objective refraction (spherical equivalent), 4) longer AL (mm), 5) lower corneal coma-like aberration (CA) at the pupil diameter of 6 mm, and 6) higher ocular spherical aberration (SA) of 4 mm and lower ocular SA at the pupil diameter of 6 mm in the primary study.</p><p><strong>Conclusion: </strong>Risk factors for myopia onset in emmetropic school-age children include AL, refraction, corneal CAs, and ocular SAs.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"687-693"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroprotective effect of ripasudil on retinal ganglion cells via an antioxidative mechanism.","authors":"Reiko Yamagishi-Kimura, Megumi Honjo, Makoto Aihara","doi":"10.1007/s10384-025-01243-x","DOIUrl":"10.1007/s10384-025-01243-x","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the neuroprotective effect of ripasudil, a rho-kinase inhibitor that is a commercially available glaucoma medication that lowers intraocular pressure. We explored the effects of ripasudil on retinal damage via oxidative stress (OS) in primary rat retinal ganglion cell (RGC) cultures and NMDA-induced retinal damage in mice.</p><p><strong>Study design: </strong>Experimental investigation METHODS: Primary rat RGCs were isolated via a 2-step immunopanning method and cultured under normal cultivation conditions for 72 h and for a further 24 h in antioxidant-free medium for OS. We measured the number of living RGCs by use of calcein-AM and calpain activity via calpain immunoreactivity assays. Furthermore, we evaluated the effects of ripasudil via RGC counting in retinal flat-mounts from Thy1-CFP mice, retinal thickness via optical coherence tomography, and reduced glutathione levels via GSSG/GSH assays in NMDA-induced retinal damage.</p><p><strong>Results: </strong>The living RGC counts of normal, OS, 0.1, 1, 10, and 100 uM ripasudil under OS were 236.0 ± 21.6, 155.0 ± 13.2, 155.9 ± 17.1, 158.9 ± 12.0, 184.8 ± 26.9, and 201.1 ± 24.8 cells, respectively. 10 or 100 uM ripasudil significantly inhibited the OS-induced RGC reduction (P < 0.05 or 0.01). Furthermore, the enhanced calpain activity induced by OS was suppressed by 100 uM ripasudil (P < 0.05). In an in vivo study, the RGC counts in the NMDA-treated group were lower than those of the non-NMDA-treated group. NMDA-induced RGC loss was significantly suppressed by ripasudil (P < 0.01). Retinal thinning after 3 weeks of NMDA injection was also inhibited by ripasudil (P < 0.01 or 0.05). Furthermore, NMDA increased the glutathione level, whereas ripasudil suppressed it (P < 0.05).</p><p><strong>Conclusions: </strong>Ripasudil may have neuroprotective effects via an antioxidative mechanism, which could be useful as an intraocular pressure-independent additive.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"823-832"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12391152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravenous immunoglobulin for the acute treatment of refractory optic neuritis in Japan.","authors":"Yohei Takahashi, Takeshi Kezuka, Keigo Shikishima, Akiko Yamagami, Hideki Chuman, Makoto Nakamura, Satoshi Ueki, Akiko Kimura, Masato Hashimoto, Sonoko Tatsui, Nobuyuki Shoji, Hitoshi Ishikawa","doi":"10.1007/s10384-025-01210-6","DOIUrl":"10.1007/s10384-025-01210-6","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the usage status and evaluate the efficacy of intravenous immunoglobulin (IVIG) for the acute treatment of optic neuritis (ON) in Japan.</p><p><strong>Study design: </strong>Multicenter retrospective case series.</p><p><strong>Methods: </strong>The study subjects were patients with steroid-resistant acute ON in whom IVIG had been initiated between January 2020 and August 2022 at 30 facilities in Japan. The clinical characteristics, visual acuity, and adverse events following IVIG were compared among anti-aquaporin 4 antibody positive ON (AQP4-ON), anti-myelin oligodendrocyte glycoprotein antibody positive ON (MOG-ON), and idiopathic ON (ION).</p><p><strong>Results: </strong>The study included sixty-five patients (76 eyes); the main clinical department administering IVIG was ophthalmology (50 cases, 77.0 %). 43 cases had their first ON attack and 22 cases had recurrent ON. Plasmapheresis (PP) was combined in 21 cases. The efficacy endpoint, changes in logarithm of the minimum angle of resolution (logMAR) after IVIG compared with preIVIG, showed statistically significant improvement in the AQP4-ON group at one week, 4 weeks, and 12 weeks after IVIG (p=0.015, p<0.001, p<0.001, respectively). In the MOG-ON group, excluding cases with combined PP, logMAR post IVIG did not improve significantly compared with preIVIG. Among the ION group, compared with preIVIG, logMAR at 4weeks and 12 weeks post IVIG were statistically significant improved (p=0.019, p=0.023, respectively). Adverse events occurred in 7 patients with IVIG. 4 of the 7 patients continued the IVIG treatment, and 3 patients discontinued it within 5 days.</p><p><strong>Conclusion: </strong>This study demonstrates that IVIG may be an effective new option for acute treatment of steroid-resistant ON as an add-on to conventional therapy.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"775-788"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12391192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes, including intraocular inflammation, after intravitreal brolucizumab for diabetic macular edema.","authors":"Takao Hirano, Yoshiaki Chiku, Ken Hoshiyama, Yoshiaki Takahashi, Shun Ito, Toshinori Murata","doi":"10.1007/s10384-025-01226-y","DOIUrl":"10.1007/s10384-025-01226-y","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to assess the real-world outcomes, including intraocular inflammation (IOI), following administration of intravitreal brolucizumab (Beovu 6.0 mg/0.05 mL; Novartis) injections (IVBr) for diabetic macular edema (DME).</p><p><strong>Study design: </strong>Retrospective study.</p><p><strong>Methods: </strong>A total of 56 eyes of 47 patients with DME were treated with IVBr for a minimum follow-up of at least 6 months between May 2022 and November 2023. A \"non-strict pro re nata\" dosing protocol for IVBr was used. The best corrected visual acuity (BCVA), central macular thickness (CMT), at baseline, 6 months, 1 year, and the latest visit date and IVBr frequency were assessed to evaluate the treatment efficacy. IOI incidence, baseline characteristics of patients with IOI, and treatment course were investigated.</p><p><strong>Results: </strong>BCVA significantly improved at 6 months and at the latest visit compared to baseline (P = 0.008 and 0.006, respectively). CMT was significantly thinner at 6 months, 1 year, and the latest visit compared to baseline (all, P < 0.001). In 46 eyes followed for more than 1 year, the number of IVBr from baseline to 1 year was 3.8 ± 1.9. Four eyes (7.1%) of four patients (8.5%) developed IOI during the observation period. All patients were women, with an average age of 70.8 ± 9.0 years (59-81 years). Upon IOI diagnosis, all patients received posterior sub-Tenon's triamcinolone acetonide and topical betamethasone sodium phosphate, resulting in rapid resolution.</p><p><strong>Conclusion: </strong>IOI developed in four of 56 (7.1%) eyes and responded well to prompt steroid therapy after 1.5 years of IVBr use for DME. BCVA and CMT improved at all evaluation time points. With an average of 3.8 IVBr injections per year, IVBr showed long-term efficacy for DME in the real-world setting, although the occurrence of IOI should be monitored.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"724-731"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12391142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Choroidal changes after vitrectomy performed for macular hole retinal detachment.","authors":"Hirotaka Sumida, Ikuko Umeda, Takayuki Baba","doi":"10.1007/s10384-025-01218-y","DOIUrl":"10.1007/s10384-025-01218-y","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate changes in the choroidal area (CA), luminal area (LA), stromal area (SA), choroidal vascularity index (CVI), and choroidal thickness (CT) before and after vitrectomy in eyes with macular hole retinal detachment (MHRD).</p><p><strong>Study design: </strong>Retrospective observational study.</p><p><strong>Methods: </strong>We measured the best-corrected visual acuity (BCVA), intraocular pressure (IOP), CA, LA, SA, CVI, and CT preoperatively and 1, 3, and 6 months postoperatively in 10 eyes with MHRD. CA was measured within a 3-mm-wide area around the fovea in the horizontal and vertical images. LA and SA were quantified using the Niblack method, and CVI was calculated as the ratio of LA to CA. CT was measured at the subfovea and at 1 and 3 mm vertically and horizontally away from the fovea.</p><p><strong>Results: </strong>BCVA improved significantly at 1 and 3 months postoperatively (P = 0.036 and 0.016). IOP remained stable. CA and LA decreased significantly 6 months postoperatively in both the horizontal (P = 0.002 and 0.014) and vertical sections (P = 0.006 and 0.002). SA remained stable. CVI reduced significantly at 1 month horizontally and at 3 months vertically (both P = 0.027). CT decreased significantly in the subfovea at 3 and 6 months postoperatively (P = 0.027 and 0.020, respectively). Significant reductions were also observed at 1 mm nasal, temporal, and superior regions (P = 0.014, 0.014, and 0.004) and at 2 mm temporal and superior regions 1 month postoperatively (P = 0.020 and 0.014).</p><p><strong>Conclusion: </strong>Choroidal thinning was observed after vitrectomy in eyes with MHRD, driven by a reduction in the luminal area.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"755-765"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of biosimilar infliximab CT-P13 in the treatment of refractory uveitis associated with Behçet's disease.","authors":"Chiuping Lee, Masaki Takeuchi, Tatsukata Kawagoe, Jutaro Nakamura, Etsuko Shibuya, Mami Ishihara, Norihiro Yamada, Yuki Mizuki, Akira Meguro, Yohei Kirino, Yutaro Soejima, Lisa Hirahara, Yuki Iizuka, Nobuhisa Mizuki","doi":"10.1007/s10384-025-01206-2","DOIUrl":"10.1007/s10384-025-01206-2","url":null,"abstract":"<p><strong>Purpose: </strong>This study evaluated the effectiveness and safety of the biosimilar infliximab CT-P13 in treating refractory uveitis associated with Behçet's disease.</p><p><strong>Study design: </strong>Retrospective study.</p><p><strong>Methods: </strong>A retrospective analysis of medical records from seven patients was conducted, categorizing them into two groups: those initially treated with CT-P13 (Group 1) and those switched from other tumor necrosis factor inhibitors (Group 2). Data on demographics, treatment duration, ocular inflammatory attacks, visual acuity changes, relapse rates, and adverse events were collected.</p><p><strong>Results: </strong>Seven patients (mean age: 32.0 ± 17.7 years) with refractory uveitis associated with Behçet's disease were included. Four patients in Group 1 received CT-P13 as their first-line biologic therapy, of whom two (50%) achieved remission. All patients exhibited a significant reduction in relapses in the 6 months before and after CT-P13 treatment (Wilcoxon test, p = 0.031). Three patients in Group 2, switched from original infliximab, maintained remission for an average of 11.0 ± 2.0 months. Overall, 71.4% of patients achieved remission. No significant changes in visual acuity were observed in either group. One adverse event occurred, but no adverse drug reactions were reported.</p><p><strong>Conclusion: </strong>The biosimilar infliximab CT-P13 appears to be an effective and cost-efficient option for managing refractory uveitis in Behçet's disease. This finding highlights its potential in managing this challenging condition and warrants further investigation in larger patient cohorts.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"798-804"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144008699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of no-history formulae for intraocular lens power calculation in post-myopic laser vision correction eyes: a multicenter study in Japan.","authors":"So Goto, Yosai Mori, Hidemasa Torii, Yumi Hasegawa, Takashi Kojima, Kazutaka Kamiya, Takuya Shiba, Kazunori Miyata","doi":"10.1007/s10384-025-01217-z","DOIUrl":"10.1007/s10384-025-01217-z","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the refractive prediction accuracy of seven no-history intraocular lens (IOL) power calculation formulas in post-myopic laser vision correction (M-LVC) eyes in Japanese patients.</p><p><strong>Study design: </strong>Multicenter retrospective case series.</p><p><strong>Methods: </strong>This study included patients with previous M-LVC who underwent cataract surgery between 2016 and 2023. IOL power calculation formulas were assessed using measurements from a swept-source optical coherence biometer. Refractive prediction errors were calculated for the Emmetropia Verifying Optical 2.0 (EVO 2.0), Post Myopic LASIK/PRK Hoffer QST (Hoffer QST), and Post-M-LVC PEARL-DGS (PEARL-DGS) formulas. These results were compared with those obtained from the Barrett True-K No History (BTKNH), Haigis-L, Shammas, and ASCRS average formulas. Heteroscedastic testing for root mean square absolute error (RMSAE) was used to evaluate formula performance.</p><p><strong>Results: </strong>The study comprised 125 post-LASIK eyes from 89 patients. Only the BTKNH had mean numerical errors not significantly different from zero. The formulas were ranked by absolute prediction error (MAE): ASCRS average (0.42 D), BTKNH (0.43 D), Hoffer QST (0.46 D), Pearl-DGS and Shammas (0.46 D), EVO 2.0 (0.48 D), and Haigis-L (0.51 D). The BTKNH and ASCRS average demonstrated smaller RMSAE compared to Shammas (P < .0001). The Hoffer QST had a smaller RMSAE than Pearl-DGS (P = 0.02).</p><p><strong>Conclusion: </strong>The BTKNH, ASCRS average, and Hoffer QST formulas are precise and reliable for improving postoperative refractive outcomes in Japanese patients with a history of M-LVC.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"717-723"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}